BiologIC contributes to Phacilitate Automation Report 2019

Advanced Therapies (ATs) are a hugely exciting area of medicine although the very first regulatory cleared ATs have significant cost of goods. Decentralised manufacturing of these therapies – potentially at the point of need – is seen as a potential solution to the cost of goods issue amongst other challenges.

BiologIC recently contributed to the Phacilitate Automation report 2019 where we discuss decentralised manufacturing of ATs in the healthcare setting and the challenges of getting clinicians and the healthcare systems on-board with this.

In this piece we identify user needs for the decentralised manufacturing scenario and then consider what is required to realise the potential of decentralised manufacturing to address the current challenges in the AT sector.

We’d love to hear your thoughts and opinions on this, get in touch on This email address is being protected from spambots. You need JavaScript enabled to view it.